Vernalis plc

Vernalislog

 

Vernalis plc, the parent company of Vernalis Therapeutics, Inc. is one of the UK’s leading pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses, our own research activities and from in-licensing. 

 The strategy is to:

  • Build a profitable and cash generative business
  • Develop and commercialise low development-risk late-stage differentiated pharmaceutical products for unmet medical needs in the US
  • Partner all of our NCE drug candidates
  • Leverage our structure- and fragment-based drug discovery expertise through collaborations with other companies

For more information please visit us at www.vernalis.com.

 

Latest News

FDA Issues a Complete Response Letter on CCP-07 NDA

Vernalis plc announces today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-07.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch